Pluripotent Stem Cells in Eye Disease Therapy
74,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

This book discusses applications of pluripotent stem cells to study eye disease in vitro and to create novel therapies for degenerative eye diseases. Chapters are contributed by experts in the field and cover such topics as the use of pluripotent stem cells in 2D and 3D engineering of ocular tissues for disease modelling and drug testing as well as approaches to replace degenerated RPE and photoreceptors in macular degeneration and retinitis pigmentosa.
Pluripotent Stem Cells in Eye Disease Therapy presents a comprehensive discussion of basic science and clinical applications and is an…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book discusses applications of pluripotent stem cells to study eye disease in vitro and to create novel therapies for degenerative eye diseases. Chapters are contributed by experts in the field and cover such topics as the use of pluripotent stem cells in 2D and 3D engineering of ocular tissues for disease modelling and drug testing as well as approaches to replace degenerated RPE and photoreceptors in macular degeneration and retinitis pigmentosa.

Pluripotent Stem Cells in Eye Disease Therapy presents a comprehensive discussion of basic science and clinical applications and is an indispensable resource for everyone from advanced graduate students to advanced professionals who want to learn about the potential of stem cell biology and its role in the field of retinal diseases.
Autorenporträt
Dr. Kapil Bharti holds a bachelor's degree in Biophysics from the Panjab University, Chandigarh, India, a master's degree in biotechnology from the M.S. Rao University, Baroda, India. He obtained his Ph.D. from J.W. Goethe University, Frankfurt, Germany, graduating summa cum laude. His Ph.D. work involved research in the areas of heat stress, chaperones, and epigenetics.  He did his postdoc at the National Institutes of Health, where he published numerous papers in the areas of transcription regulation, pigment cell biology, and developmental biology of the eye. After his postdoc, he joined the National Eye Institute as their first Earl Stadtman Tenure-Track Investigator. His lab was recently awarded two prestigious grants: 1) the only Intramural Common Fund grant to develop a phase I Investigational New Drug (IND) for Autologous induced pluripotent stem cell derived retinal pigment epithelium tissue; and 2) a DoD grant to develop a 3D-retina tissue to model retinaldiseases in vitro. His current work as a Senior Investigator and the head of the Unit on Ocular and Stem Cell Translational Research involves understanding mechanism of retinal degenerative diseases using induced pluripotent stem cell technology, and developing cell-based and drug-based therapies for such diseases.